Breakthrough for allergy vaccination

Danish biopharmaceutical company ALK-Abelló has presented good results from a major allergy study

Allergy vaccination with Alutard SQ, produced by the Danish biopharmaceutical company ALK-Abelló, has been documented to be an effective treatment of hay fever caused by grass pollen. Results from the world’s largest clinical study of allergy vaccination have been presented at a US congress for specialist physicians in allergy. Leading researchers are reportedly referring to the results as an international breakthrough.

In the UK where the clinical study was carried out, 10% of the population suffers from grass allergy. In Denmark and the rest of Europe the proportion is estimated to be around 7%. MD of ALK-Abelló Jens Bager comments that although Alutard SQ has been on the market for some years, the new test results confirm that allergy vaccination should have a central role in the treatment of allergy in the future. ALK-Abelló is a world leader in allergy vaccination and a part of the Chr. Hansen Group. The news is reported by national broadsheet Jyllands-Posten.